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Background: Inhalants are among the most common and dangerous forms of substance use, 
but very little research on inhalant use disorders exist. Unlike other substances, the Diagnostic 
and Statistical Manual, 4th edition (DSM-IV) indicates that inhalants do not have an associated 
withdrawal syndrome among persons who meet criteria for inhalant dependence.
Methods: Using data from the National Epidemiologic Survey on Alcohol and Related 
Conditions, this study examines the prevalence of withdrawal symptoms among inhalant 
users. Prevalence of inhalant withdrawal symptoms for inhalants was also compared with the 
prevalence of cocaine withdrawal symptoms to help determine the presence of an inhalant 
withdrawal syndrome.
Results: Approximately 47.8% of persons who met criteria for inhalant dependence reported 
experiencing three or more inhalant-related withdrawal symptoms that were clinically signifi-
cant. Among those with inhalant dependence, almost half of the withdrawal symptoms were 
as common as the corresponding withdrawal symptoms experienced by persons with cocaine 
dependence. Furthermore, the percentage of persons with inhalant dependence reporting clini-
cally significant inhalant withdrawal symptoms was almost equal to the percentage of persons 
with cocaine dependence reporting clinically significant cocaine withdrawal symptoms.
Conclusions: These data provide evidence for an inhalant-related withdrawal syndrome among 
persons with inhalant dependence. Revisions to DSM-IV should consider including inhalant 
withdrawal as a diagnostic criterion for this disorder.
Keywords: Inhalants, volatile solvents, withdrawal, inhalant use disorders
Introduction
Due to high risk for morbidity and mortality, inhalants are among the most dangerous 
forms of substance use;1,2 however, very little research on inhalant use disorders exists.3 
The general absence of knowledge is apparent, as reflected in the short description of 
inhalant use disorders in the Diagnostic and Statistical Manual, 4th edition (DSM-IV).3 
In particular, DSM-IV has included virtually no information regarding prevalence, 
course, subtypes, comorbid medical and mental health conditions, and specific age, 
gender, and sociodemographic features.
Recent findings have raised questions about the validity of DSM-IV criteria for 
inhalant use disorders.4 One serious challenge to the validity of inhalant dependence 
is that inhalant withdrawal symptoms are not considered to be   present among inhalant 
users and therefore not part of the diagnostic criteria for making a DSM-IV depen-
dence diagnosis.3,5 This decision was based on expert   consensus rather than empirical 
evidence. At present, the DSM-V substance use disorder workgroup has proposed Substance Abuse and Rehabilitation 2011:2 submit your manuscript | www.dovepress.com
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including inhalant   withdrawal as part of a   unidimensional 
inhalant use disorder (see http://www.dsm5.org/). How-
ever, this decision is not grounded in evidence. In fact, at 
the time of preparing this report, the DSM-V workgroup 
provides only a single citation in the rationale for proposed 
changes to inhalant use disorders specific to withdrawal. 
This citation is from alcohol research.6 As shown in a recent 
review, existing data from human and animal studies have 
suggested the presence of an inhalant withdrawal syndrome, 
especially among frequent or heavy inhalant users.5 How-
ever, to date, no study has systematically examined inhal-
ant withdrawal among human subjects. Data from a large 
national sample could provide some evidence to guide the 
DSM-V workgroup.
A stronger knowledge base about inhalant-related 
  symptoms is needed, as establishing the presence or absence 
of an inhalant withdrawal syndrome is critical to advanc-
ing the clinical assessment and treatment for inhalant use 
  disorders. Valid diagnostic criteria are also necessary to 
ensure proper diagnosis of inhalant users and facilitate their 
timely access to treatment. Therefore, the purpose of this 
study was to examine the prevalence of withdrawal symp-
toms among inhalant users, and determine whether the data 
would support the presence of a withdrawal syndrome among 
inhalant-dependent users. The study sample was drawn from 
a nationally representative sample of inhalant users, a large 
national study that is presently known to contain the most 
comprehensive set of inhalant-specific withdrawal symp-
toms. Currently, no standards exist that indicate the extent 
to which withdrawal symptoms must occur for a given class 
of substances in order for withdrawal to be considered a reli-
able and valid indicator of substance dependence. Thus, to 
help contextualize the findings we compared the prevalence 
of inhalant withdrawal symptoms among persons who met 
DSM-IV criteria for inhalant dependence with the preva-
lence of cocaine withdrawal symptoms among persons who 
met DSM-IV criteria for cocaine dependence. We selected 
cocaine as a comparison group, given that the literature has 
clearly established a withdrawal syndrome for this substance.7 
It should be noted that cannabis was not selected as a com-
parison group, as cannabis withdrawal is not recognized in 
DSM-IV because of doubts regarding its clinical significance 
at the time that DSM-IV was prepared.8 Nicotine was not 
used as a comparison, as the mechanisms and consequences 
of nicotine withdrawal are likely to exhibit fundamental dif-
ferences. This is the first study to systematically examine 
inhalant withdrawal symptoms among humans, which fills a 
critical gap in inhalant research.
Material and methods
Subjects, sampling, and interviews
This study used data from the 2001–2002 National Epidemio-
logic Survey on Alcohol and Related Conditions (NESARC), 
a representative sample of 43,093 US adults, which gathered 
information on substance use and comorbid conditions from 
individuals living in households and group settings.9 This 
research was conducted with necessary permissions and 
complies with Institutional Review Board standards with 
respect to secondary data analysis. NESARC utilized a multi-
stage sampling design and had an overall response rate of 81%. 
Data were weighted at the individual and household levels and 
adjusted for oversampling, nonresponse, and to be representa-
tive of the US population vis-à-vis the 2000 census. US Census 
Bureau workers administered the Alcohol Use Disorders and 
Associated Disabilities Interview Schedule (AUDADIS-IV), 
a structured interview designed for administration by lay 
interviewers. AUDADIS-IV assesses DSM-IV mental health 
and substance use disorders with good reliability.9,10
Measurement
inhalant use and inhalant use disorder
Inhalant users were identified in the overall sample with 
the following question: “Have you ever used inhalants or 
  solvents; for example, amyl nitrite, nitrous oxide, glue, 
toluene, or gasoline?” An introductory statement preceding 
the inhalant question informed respondents that they were 
to report inhalants used on their own, without a doctor’s 
prescription, and for the purposes of getting high, enjoy-
ing themselves, relaxing, feeling better, feeling more alert, 
  quieting their nerves, or to see how they would work. Inhalant 
abuse was assigned to inhalant users who met DSM-IV inhal-
ant abuse criteria but who did not meet inhalant dependence 
criteria; inhalant dependence was assigned to subjects who 
met DSM-IV inhalant dependence criteria.3
inhalant withdrawal symptoms
The AUDADIS-IV contained a structured assessment of 
18 substance-specific withdrawal symptoms for all substance 
classes. As described in Hasin et al, these questions addressed 
symptoms after cessation of use (ie, morning after or within 
the first few days of use).11 Inhalant-specific withdrawal symp-
toms are summarized in Table 1. The clinical significance of 
withdrawal was defined as the presence of two or more inhal-
ant withdrawal symptoms and significant distress or impair-
ment in social, occupational, or other life domains. Because 
the number of withdrawal symptoms required for meeting Substance Abuse and Rehabilitation 2011:2 submit your manuscript | www.dovepress.com
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the clinical significance criterion varies by drug (eg, opiate 
withdrawal requires three withdrawal symptoms, and cocaine 
withdrawal requires two) and it has not yet been established 
for inhalant dependence, we also created a variable indicating 
the presence of three or more inhalant withdrawal symptoms 
(for those who had two or more symptoms that were clini-
cally significant, as queried by the AUDADIS-IV). Lastly, 
the DSM-IV withdrawal criterion was calculated from the 
AUDADIS-IV inhalant withdrawal symptoms in NESARC, 
based on the presence of either 1) clinically significant with-
drawal or 2) the use of the same or a similar substance to 
avoid or alleviate the withdrawal symptoms.3,11
Analysis
Analyses were conducted using Stata version 11.12 Stata 
implements a Taylor series linearization to adjust standard 
errors of estimates for complex survey sampling design 
effects involving clustered data. Percentages for each abuse 
and dependence criterion, withdrawal symptom, and other 
withdrawal characteristics were computed for all lifetime 
inhalant users. These percentages were also reported for 
each mutually excluded DSM-IV classification of inhalant 
use disorder (ie, no disorder, abuse, dependence). We also 
reported the prevalence of cocaine withdrawal symptoms and 
other characteristics among persons with cocaine dependence 
for comparative purposes. However, given the high rate of 
drug-related comorbidities among inhalant users,13 statistical 
comparisons between respondents with inhalant dependence 
and cocaine dependence could not be performed. More specifi-
cally, mutually exclusive groups could not be established while 
achieving minimum cell counts for statistical comparisons.
Results
Characteristics of inhalant users
Overall, there were 664 inhalant users in the NESARC 
(unweighted). Approximately 74.2% of lifetime inhalant 
Table 1 Prevalence of withdrawal symptoms among persons with DSM-IV inhalant use disorders and cocaine dependence
Withdrawal  
symptom
Lifetime  
inhalant use  
n = 644  
% (SE)
DSM-IV inhalant use disorder classification Cocaine  
dependenced   
n = 390  
% (SE)
No disorder  
n = 526  
% (SE)
Inhalant  
abusea  
n = 117  
% (SE)
Inhalant  
dependenceb  
n = 21  
% (SE)
χ2 test with  
design-based  
corrected F (P)c
hypersomnia 4.4 (0.98) 1.7 (0.63) 9.4 (2.79) 63.6 (13.9) 62.9 (,0.001) 57.4 (3.41)
Feeling weak and tired 7.9 (1.14) 4.0 (0.99) 20.0 (4.26) 55.4 (15.16) 28.5 (0.001) 77.3 (2.7)
Depressed mood 4.9 (0.97) 1.3 (0.53) 17.2 (4.42)e 42.2 (15.91)e 31.6 (,0.001) 73.5 (3.16)
Sweating or fast  
heart beat
5.5 (1.05) 2.5 (0.71) 14.5 (4.16)e 45.0 (16.04)e 24.5 (,0.001) 70.0 (3.15)
nausea 4.8 (1.07) 2.1 (0.74) 12.2 (3.52) 46.0 (15.95) 28.3 (,0.001) 31.8 (3.01)
Yawning 5.2 (1.08) 2.4 (0.87) 13.7 (4.34) 39.0 (16.64) 15.9 (,0.001) 35.8 (3.27)
Runny eyes and nose 2.6 (0.62) 1.0 (0.46) 5.9 (2.21) 33.0 (16.16) 22.1 (,0.001) 59.9 (2.89)
eat more or gain  
weight
0.2 (0.12) 0.1 (0.13) 0 (0.00) 4.8 (3.04) nAf 18.4 (2.31)
Anxiety 5.4 (1.07) 1.8 (0.73) 17.4 (4.53)e 41.8 (15.89)e 25.4 (,0.001) 77.2 (2.53)
Muscle aches 2.9 (0.82) 2.0 (0.73) 6.0 (3.38)e 11.0 (6.30)e nAf 11.4 (1.81)
Fever 1.9 (0.58) 0.3 (0.26) 5.2 (2.28) 33.9 (17.21) nAf 11.4 (1.81)
Restlessness 3.1 (0.80) 1.8 (0.78) 6.8 (2.53) 21.6 (12.14) nAf 66.7 (3.05)
Psychomotor  
retardation
3.7 (0.81) 2.2 (0.70) 8.2 (3.14)e 27.1 (16.27)e 9.1 (,0.001) 24.3 (2.56)
Sweating 2.4 (0.80) 0.9 (0.50) 4.9 (2.09) 38.0 (16.11) nAf 53.14 (3.17)
Vivid dreams 3.1 (0.82) 1.5 (0.71) 10.1 (3.36)e 7.7 (4.35)e 11.3 (,0.001) 34.4 (2.82)
hallucination 3.0 (0.69) 1.3 (0.55) 6.7 (2.39) 35.3 (16.27) 21.0 (,0.001) 30.5 (2.51)
Tremors 4.0 (0.89) 1.8 (0.76) 9.8 (3.09) 37.8 (16.7) 17.6 (,0.001) 52.1 (3.15)
insomnia 2.1 (0.58) 0.5 (0.30) 6.3 (2.40) 28.6 (16.16) nAf 61.0 (2.98)
Seizure 0.5 (0.28) 0 (0.00) 2.5 (1.59) 2.4 (2.48) nAf 5.0 (1.17)
Bad headaches 7.3 (1.25) 3.8 (1.06) 20.3 (4.70)e 30.9 (16.11)e 14.3 (,0.001) 41.6 (2.71)
Any withdrawal  
symptom
19.0 (1.89) 12.2 (1.78) 43.6 (5.32) 77.3 (12.60) 34.8 (,0.001) 98.9 (0.57)
Notes: All prevalence estimates of withdrawal symptoms are specific to the indicated drug (ie, inhalants or cocaine). awithout a lifetime history of inhalant dependence; 
bwith or without a lifetime history of abuse; cpair-wise comparisons were conducted when global test was statistically significant; dwithdrawal symptoms among cocaine 
dependence are reported for comparative purposes, but statistical comparisons were not made with inhalant use disorders because of nonmutually exclusive grouping; eall 
pair-wise comparison among inhalant use disorder groups were statistically significant except groups with this super-script; fnot applicable due to cell counts ,5.
Abbreviations: DSM-iV, Diagnostic and Statistical Manual, 4th edition; Se, standard error.Substance Abuse and Rehabilitation 2011:2 submit your manuscript | www.dovepress.com
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users were male and 82.2% were White. The majority was 
unmarried, and a substantial minority had a high school 
education or less. Only a small percentage of inhalant users 
had a DSM-IV drug use or alcohol use disorder that preceded 
inhalant use (7.8% and 9.8%). Approximately 1 in 11 (9.3%) 
inhalant users had developed a DSM-IV mood and/or   anxiety 
disorder prior to initiating inhalant use. Approximately 
one-third of the sample met criteria for conduct disorder or 
antisocial personality disorder. Approximately 22.2% had a 
family history of behavior problems, and 50.5% had a family 
history of substance use problems. The mean age of onset 
of inhalant use was 17.5 years (95% CI = 16.0–17.9), range 
of 5–44 years. Additional demographic characteristics for 
inhalant users in NESARC are described elsewhere.14
Summary of DSM-IV diagnostic criterion 
for inhalant use disorders
The prevalence of DSM-IV inhalant use disorder criteria among 
the full sample of inhalant users was low; that is, less than 13% 
for any given criterion, with the exception of a desire to or 
unsuccessful efforts to control (30.4%) (see Table 2).   However, 
a clear graded relationship among the diagnostic groups is 
present. By graded relation, we mean that those without any 
disorder have the lowest prevalence, followed by persons who 
met lifetime criteria for abuse, and then dependence.
Of the 11 inhalant abuse and dependence criteria, with-
drawal was ranked as the 7th most common criteria among 
all inhalant users. For those without an inhalant disorder, the 
ranking of withdrawal was 5th (inhalant abuse, 7th; inhalant 
dependence, 6th). Among persons with inhalant dependence, 
the majority (53.4%) experienced withdrawal. Among the 
seven inhalant dependence criteria, withdrawal ranked as 
the 6th most common. The least common was using larger 
amounts/longer periods (38.4%).
Comparison of inhalant withdrawal 
symptoms
As described in Table 1, approximately one in five inhalant 
users reporting lifetime inhalant use experienced at least one 
type of inhalant withdrawal symptom. A graded relationship 
across the DSM-IV diagnostic categories was observed for 
any lifetime history of inhalant withdrawal symptoms. More 
specifically, 12.2% of inhalant users (no disorder) reported 
any withdrawal symptom, whereas the percentages for those 
who met criteria for inhalant abuse (43.6%) or dependence 
(77.3%) were significantly higher (P , 0.001). A graded 
relationship across the DSM-IV diagnostic categories was 
also observed for each unique withdrawal symptom, with 
the exception of vivid dreams. The differences across groups 
reached significance for each group that allowed statistical 
comparisons, with the exception of muscle aches. Due to low 
cell counts and multiple comparisons, it is important that the 
differences are interpreted cautiously.
The most commonly reported withdrawal symptoms 
among persons with inhalant dependence were hypersomnia 
(63.6%), feeling tired (55.4%), and nausea (46.0%). The least 
common were seizures (2.4%), eating more or gaining weight 
(4.8%), and vivid dreams (7.7%). For comparative purposes, 
Table 2 Prevalence of DSM-IV abuse and dependence criteria among persons with lifetime inhalant use
Diagnostic criteria Lifetime 
inhalant use 
n = 644  
% (SE)
DSM-IV inhalant use disorder classification
No disorder 
n = 526  
% (SE)
Inhalant abusea 
n = 117  
% (SE)
Inhalant  
dependenceb 
n = 21  
% (SE)
A1 Failure to fulfill role obligations 7.8 (1.34) nAc 35.6 (5.19) 75.5 (10.52)
A2 hazardous use 12.5 (1.75) nAc 62.9 (5.22) 65.1 (14.65)
A3 Legal problems  1.0 (0.37) nAc 2.8 (1.46) 20.9 (11.61)
A4 Use despite social or interpersonal problems 11.6 (1.48) nAc 58.9 (5.50) 65.5 (16.24)
D1 Tolerance 3.7 (0.89) 1.0 (0.42) 9.32 (2.67) 56.7 (14.67)
D2 Withdrawal 5.6 (1.12) 1.6 (0.65) 18.1 (4.74) 53.4 (15.33)
D3 Larger amounts/longer periods 4.7 (0.85) 1.7 (0.66) 14.7 (3.44) 38.4 (13.62)
D4 Desire to or unsuccessful efforts to control 30.4 (2.27) 24.7 (2.48) 49.6 (5.35) 87.2 (11.72)
D5 Great deal of time spent 7.3 (1.12) 2.6 (0.87) 19.9 (3.92) 79.1 (11.65)
D6 Activities given up or reduced 4.1 (0.82) 0.6 (0.37) 11.6 (3.23) 70.1 (12.37)
D7 continued use despite psychological or 
physical problems
7.0 (1.20) 2.1 (0.74) 21.9 (4.32) 68.5 (13.90)
Notes: awithout a lifetime history of inhalant dependence; bwith or without a lifetime history of abuse; cnot applicable, as endorsement of any of these criterion qualifies the 
respondent for an inhalant abuse disorder.
Abbreviations: DSM-iV, Diagnostic and Statistical Manual, 4th edition; Se, standard error.Substance Abuse and Rehabilitation 2011:2 submit your manuscript | www.dovepress.com
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the percentages of cocaine withdrawal symptoms among 
persons with cocaine dependence are presented in Table 1. 
However, formal statistical tests between the inhalant and 
cocaine groups were not possible, given that the groups are 
not mutually exclusive. A visual inspection of the percent-
ages suggested that 6 of the 21 withdrawal symptoms among 
inhalant-dependent individuals occurred as prevalent or more 
prevalent than the corresponding rates among cocaine-depen-
dent individuals. Prior research has not clearly defined how 
many drug users must exhibit a given withdrawal symptom for 
it to be considered frequently occurring. If the threshold is set 
at 30%, 13 unique   inhalant withdrawal symptoms would be 
considered frequently occurring among persons with inhalant 
dependence, and 15 unique cocaine withdrawal symptoms 
would be considered frequently occurring among persons 
with cocaine   dependence. If the threshold is set at 50%, two 
inhalant withdrawal symptoms and 10 cocaine withdrawal 
symptoms would be considered frequently occurring.
Comparison of withdrawal summary 
characteristics
Summary variables revealed that individual withdrawal 
symptoms and an analog of the DSM-IV withdrawal criteria 
were experienced most frequently among those with inhal-
ant dependence (see Table 3). Persons without a disorder 
exhibited the lowest frequency of withdrawal symptoms, 
followed by persons with abuse. The mean number of inhalant 
withdrawal symptoms among those with inhalant dependence 
was 6.5. A regression model of all inhalant users revealed 
that the mean number of withdrawal symptoms was signifi-
cantly different across the diagnostic groups, and a series of 
pairwise comparisons showed differences across the groups 
(P , 0.05). Again, these tests must be interpreted conser-
vatively due to low cell counts and multiple comparisons. 
Based on a visual inspection, the mean number of withdrawal 
symptoms for those with inhalant dependence was slightly 
lower than the mean number of withdrawal symptoms among 
those with cocaine dependence (9.2). The percentage of 
persons with inhalant dependence who reported two or 
more withdrawal symptoms that were clinically significant 
(49.2%) was close to the percentage of those with cocaine 
dependence (48.9%). The percentages remained close when 
the threshold was increased to three, with at least two being 
clinically significant (inhalant dependence = 47.8%; cocaine 
dependence = 48.7%). However, almost half of persons with 
cocaine dependence (48.0%) used substances to avoid bad 
after effects, whereas only 10.3% of persons with inhalant 
dependence did. Again, it should be noted that comparisons 
between inhalant and cocaine dependence were based on 
visual inspections. Lastly, the DSM-IV criterion (experienc-
ing more than two withdrawal symptoms that cause clinically 
significant distress, or using the same or a similar substance 
to avoid withdrawal) was experienced significantly more 
often in those with inhalant dependence (53.4%) as compared 
with those with inhalant abuse (18.1%) or use (1.6%). The 
withdrawal criterion was experienced slightly more often in 
those with cocaine dependence (69.8%).
Conclusion
Reprise of findings
To date, the majority of research on inhalant withdrawal 
among human subjects has utilized a case study method.5 
This line of research provided an argument for the presence 
of a withdrawal syndrome among heavy users of inhalants. In 
the current study, we provide empirical support for inhalant 
withdrawal syndrome in a community sample of inhalant 
users who met DSM-IV criteria for inhalant dependence. 
Overall, these data show a high prevalence of withdrawal 
symptoms among inhalant-dependent inhalant users. Among 
those with inhalant dependence, almost half of the withdrawal 
symptoms were as common as the corresponding withdrawal 
symptoms experienced by persons with cocaine dependence. 
Furthermore, the percentage of persons with inhalant depen-
dence reporting clinically significant inhalant withdrawal 
symptoms was almost equal to the percentage of persons with 
cocaine dependence reporting clinically significant cocaine 
withdrawal symptoms. These data provide initial evidence 
for the existence of an inhalant withdrawal syndrome. That 
is, over half the persons who met criteria for dependence 
also experienced clinically significant withdrawal, providing 
empirical evidence for the addition of inhalant withdrawal as 
a diagnostic criterion in future revisions of the DSM.
A particularly interesting finding was the difference in 
manifestation of inhalant withdrawal symptoms and cocaine 
withdrawal symptoms. As previously indicated, almost half 
of persons with cocaine dependence use cocaine to avoid 
bad after effects, whereas only 10.3% of persons with inhal-
ant dependence did. In addition, the symptom “eat more or 
gain weight” was reported by approximately one in five of 
those with cocaine dependence, but only one in 20 of those 
with inhalant dependence. Assuming the existence of an 
inhalant withdrawal syndrome, these data suggest a clear 
difference in manifestation with cocaine and possibly other 
substances. This suggests further work needs to be done on 
the assessment and construct validity of inhalant withdrawal. 
Ideally, it would be useful to know which symptoms are Substance Abuse and Rehabilitation 2011:2 submit your manuscript | www.dovepress.com
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Evidence for an inhalant withdrawal syndrome
most   common among inhalant users, especially for different 
types of inhalants.
Study limitations
It is important to consider these findings and recommenda-
tions in context of the study limitations. Most notably, the 
unweighted sample size of those who met DSM-IV criteria 
for dependence was small (n = 21), which makes these 
estimates less precise than estimates for other substances 
(eg, cocaine). However, the list of withdrawal symptoms is 
comprehensive and represents a substantial improvement 
over the case study approach.5 Another consideration is the 
issue of comorbid substance use disorders among inhalant 
users. Prior research revealed that the lifetime prevalence of 
comorbid substance use disorders among NESARC inhal-
ant users was 96%.14 Given the high rate of comorbidity, it 
is nearly impossible to define a sample of persons who use 
inhalants only. A subset of poly-drug users may not be able to 
effectively discern whether inhalant symptoms are due to only 
inhalants or possibly other substances. For the same reasons, 
it would be difficult to identify characteristics of inhalant-
only users in a purely clinical sample. However, in a study 
of cannabis withdrawal, Hasin et al found that the prevalence 
of each withdrawal symptom was very close in a frequent 
cannabis user group (use of cannabis three or more days a 
week) with comorbidity and a cannabis-only subset (users 
who never had five or more drinks on a single occasion and 
never used other drugs three or more days a week).11 Further 
investigation is necessary to establish the extent to which the 
inhalant withdrawal symptoms are specific to inhalant use. It 
would be reasonable to focus initially on the most commonly 
occurring withdrawal symptoms observed in this national 
survey (ie, hypersomnia, depressed mood, feeling weak and 
tired, and nausea). For those with comorbid drug dependence 
disorders, it would also be helpful to know whether these 
symptoms are strongly associated with withdrawal symptoms 
resulting from use of other drugs. This would help define 
symptom specificity.
The most complicated issues to be addressed relate to the 
within-group heterogeneity of inhalant use. Inhalants represent 
the only substance based on the mode of administration rather 
than specific agent or chemical property.15 Prior research has 
also revealed that inhalant users may use multiple inhalant 
products. For example, Wu and Ringwalt examined inhal-
ant use among a nationally representative sample of adult 
inhalant users and found that 22.6% used two different types 
of inhalant products, and 15.5% used three or more inhalant 
products.16 In another study, using a large sample of adolescent 
inhalant users, Howard et al found that 47.9% of individuals 
reporting lifetime inhalant use had tried four or more inhalant 
products.17 This raises questions as to whether certain products 
are more likely to give rise to inhalant withdrawal symptoms 
than other products. Qualitative research that addresses the 
phenomenology of inhalant use can help us understand what 
other withdrawal symptoms might be unique to inhalants 
(between group differences), in addition to helping link specific 
withdrawal symptoms to specific inhalant products. This is a 
critical issue to address, as the physiological and psychological 
processes associated with the various inhalant products may 
be fundamentally different from each other.15
Conclusions and future directions
Overall, this study found support for the presence of with-
drawal symptoms and an inhalant withdrawal syndrome 
among persons who meet criteria for inhalant dependence. 
Including withdrawal as a diagnostic criterion for inhalant use 
disorders in the next revision of the DSM is warranted given 
the prevalence and clinical significance of these symptoms. 
Future research needs to improve on screening of inhalant 
use in general and the assessment of withdrawal symptoms 
specifically. This may help to reveal which withdrawal 
symptoms are specific to inhalants, or whether the symptoms 
manifest in conjunction with other drugs, and to inform the 
designs of effective treatment approaches specific to address-
ing inhalant dependence. Nonetheless, when inhalant users 
are identified in the addiction treatment setting, medical 
management of their withdrawal symptoms is an important 
aspect in addressing each of the DSM characteristics.
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